Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Mast Cell Activation Syndrome, Mast Cell Activation Disorder Idiopathic
In brief
This study will determine if FSD201 reduces the average daily 24-hour recall pain intensity after 28 and 56 days of treatment in adults with chronic widespread musculoskeletal nociplastic pain.
Key facts
- Study ID
- NCT05652907
- Run by
- Quantum Biopharma
- People needed
- 2
- Starts
- 2023-01-19
- Expected to finish
- 2023-05-24
- Last updated by the study team
- 2026-04-21
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Saint Charles Clinical Research — Weldon Spring, Missouri, United States
- Norman Marcus Pain Institute — New York, New York, United States
- Toronto Rehabilitation Institute — Toronto, Ontario, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.